IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General Population

What this Trial Is About

Researchers are studying changes in the magnetic properties of heart muscle tissue caused by disease, which can be detected using T1 and T2 mapping with cardiovascular magnetic resonance (CMR). This research aims to establish reliable normal ranges and diagnostic accuracy for these imaging methods across different CMR sequences, vendors, and magnetic field strengths. The study also explores how these measurements relate to clinical factors and cardiovascular risks, including in patients with suspected heart inflammation such as those recently affected by COVID-19 infection or vaccination. Participants will undergo a detailed cardiovascular imaging process including CMR with a contrast agent (gadobutrol 0.1 mmol/kg) to assess tissue mapping, heart volumes, function, strain, and late gadolinium enhancement (LGE). Additional assessments include transthoracic echocardiography, blood tests, and cardiopulmonary exercise testing. The study plans to recruit about 3000 subjects, with equal numbers scanned at 1.5 and 3.0 Tesla magnetic field strengths. During the study, participants will be monitored for outcomes such as all-cause mortality at 1 and 5 years, as well as heart failure, cardiovascular, and arrhythmia events over the same periods. The research includes healthy volunteers and those with suspected subclinical heart disease. The findings aim to improve cardiovascular risk assessment using advanced imaging techniques, with long-term follow-up extending to 5 years or more.

IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION